Characterization of test positivity among patients with coronavirus disease 2019 (COVID-19) in three electronic health records databases, February–November 2020
-
Published:2022-06-18
Issue:1
Volume:22
Page:
-
ISSN:1471-2458
-
Container-title:BMC Public Health
-
language:en
-
Short-container-title:BMC Public Health
Author:
Saunders-Hastings Patrick,Zhou Cindy Ke,Hobbi Shayan,Wong Hui-Lee,Lloyd Patricia,Boyd Eva,Alawar Nader,Clarke Tainya C.,Beers Jeff,Burrell Timothy,Shoaibi Azadeh
Abstract
Abstract
Background
Monitoring COVID-19 testing volumes and test positivity is an integral part of the response to the pandemic. We described the characteristics of individuals who were tested and tested positive for SARS-CoV-2 during the pre-vaccine phase of the pandemic in the United States (U.S.).
Methods
This descriptive study analyzed three U.S. electronic health record (EHR) databases (Explorys, Academic Health System, and OneFlorida) between February and November 2020, identifying patients who received an interpretable nucleic acid amplification test (NAAT) result. Test-level data were used to characterize the settings in which tests were administered. Patient-level data were used to calculate test positivity rates and characterize the demographics, comorbidities, and hospitalization rates of COVID-19-positive patients.
Results
Over 40% of tests were conducted in outpatient care settings, with a median time between test order and result of 0–1 day for most settings. Patients tested were mostly female (55.6–57.7%), 18–44 years of age (33.9–41.2%), and Caucasian (44.0–66.7%). The overall test positivity rate was 13.0% in Explorys, 8.0% in Academic Health System, and 8.9% in OneFlorida. The proportion of patients hospitalized within 14 days of a positive COVID-19 NAAT result was 24.2–33.1% across databases, with patients over 75 years demonstrating the highest hospitalization rates (46.7–69.7% of positive tests).
Conclusions
This analysis of COVID-19 testing volume and positivity patterns across three large EHR databases provides insight into the characteristics of COVID-19-tested, COVID-19-test-positive, and hospitalized COVID-19-test-positive patients during the early phase of the pandemic in the U.S.
Funder
U.S. Food and Drug Administration
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference32 articles.
1. US CDC. Coronavirus disease 2019 (COVID-19): cases in U.S. 2021. Accessed 15 Sept 2021.
2. US FDA. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices: In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 2020. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2. Accessed 15 Sept 2021.
3. US CDC. Interim Guidance for Antigen Testing for SARS-CoV-2: Evaluating the Results of Antigen Testing for SARS-CoV-2 Atlanta, GA2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html#evaluating-test-results. Accessed 15 Sept 2021.
4. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities. Geneva: World Health Organization; 2021.
5. Grantz KH, Lee EC, D'Agostino McGowan L, Lee KH, Metcalf CJE, Gurley ES, et al. Maximizing and evaluating the impact of test-trace-isolate programs: a modeling study. PLoS Med. 2021;18(4):e1003585.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献